CymaBay Therapeutics cymabay.com


Public list: BIO 2016 (619) Pharma Startups (4740) Rare Diseases (230)

CymaBay Therapeutics, formerly Metabolex, is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. The company has drawn on its deep understanding of diabetes to create a large database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. The company has four clinical-stage compounds: MBX-102/JNJ 39659100,...Show all

CymaBay Therapeutics, formerly Metabolex, is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. The company ha...Show all

Company (IPO / Went public)

Phone: 510-293-8800

Fax:

7999 Gateway Blvd.
Suite 130
Newark, 94560
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
CymaBay Therapeutics $203.3M Jul 28, 2014
See all 27 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related CymaBay Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 36 investors

Competitors

Company Status Description Investors

Intarcia Therapeutics

Boston, Massachusetts, United States
Alive / ActiveIntarcia Therapeutics is a biopharmaceutical company based in Bostom, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to delive...Show allLogin to see details

KAI Pharmaceuticals

South San Francisco, California, United States
AcquiredKAI Pharmaceuticals is a privately held, venture-backed drug discovery and development company with preclinical and clinical programs in acute cardiovascular and other diseases representing unmet medical needs. The company has applied its core expertise in the biology of PKC to develop highly potent and selective inhibitors and activators for each of the PKC isozymes for the treatment of a broad array of human diseases. KAI has received Fast-Track designation from the FDA for its lead compound, ...Show allLogin to see details
See all 27 competitors